Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of ISDN and Hydralazine for Hypertensive Heart Failure in Sub-Saharan Africa
NCT06400784Phase 4Completed
- Sponsor
- University of Abuja
- Start
- Mar 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isosorbide dinitrate and hydralazine in hypertensive heart disease (2 arms), sponsored by University of Abuja. Primary endpoint: Feasibility of the study at 18 months. Started Mar 2022; status: completed.
02
Drugs
isosorbide dinitratehydralazine
03
Conditions
hypertensive heart disease
Beyond the preview
Go deeper on NCT06400784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400784.